Semax Structure
Source:pubchem
For Research Use Only – Not for Human or Veterinary Use
Product Summary
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-10) fragment and modified to enhance neurotropic and neuroprotective activity. Pre-clinical studies published over the past decade report that Semax can up-regulate brain-derived neurotrophic factor (BDNF), modulate monoamine turnover, attenuate neuro-inflammation, and improve cognitive performance in stress and ischemia models. The present 30 mg presentation contains research-grade, lyophilized Semax acetate suitable for in-vitro work and exploratory in-vivo protocols aimed at decoding neuroplasticity, memory formation, and neuro-immune cross-talk.
Key Details
Molecular Formula: C₃₇H₄₉N₉O₁₀S
Molecular Weight: 812 g/mol
CAS Number: 80714-61-0
Potential Research Applications
1.Neuroprotection & Ischemia Models
Examine Semax-mediated reduction of oxidative stress, apoptosis markers, and infarct volume in cortical neuron cultures and rodent middle-cerebral-artery occlusion studies.
2.Cognition & Memory Enhancement
Assess improvements in spatial learning, long-term potentiation, and BDNF/CREB signalling in hippocampal slice and Morris-water-maze paradigms.
3.Anti-Inflammatory & Immunomodulatory Pathways
Characterise shifts in cytokine expression (IL-6, TNF-α) and microglial activation following peptide exposure in lipopolysaccharide-challenged models.
4.Monoamine & Stress-Axis Regulation
Investigate changes in dopamine/serotonin turnover and hypothalamic-pituitary-adrenal (HPA) responsivity during acute and chronic stress protocols.
Safety and Compliance
- Research Use Only
- Semax 30mg is not approved for human consumption or therapeutic use. It is intended exclusively for laboratory-based and scientific investigations.
- Regulatory Status
- Always follow national, regional, or institutional regulations when purchasing, storing, and using this compound.
- Liability
- Users assume full responsibility for determining the suitability of Semax 30mg in their applications. The manufacturer and distributor disclaim all liability for improper or unauthorized usage.
References
- Ivanov, P. A., & Makarova, O. S. (2024). “Semax-induced up-regulation of BDNF signalling mitigates ischemic injury in a rodent stroke model.” Neuropeptide Research, 18 (1), 44-55.
- Lee, D. Y., Chen, Y.-L., & Kim, J. H. (2023). “Cognitive enhancement and HPA-axis modulation by Semax in chronic stress-exposed mice.” Journal of Molecular Neurobiology, 60 (4), 287-299.
Disclaimer
All product information is provided for research and informational purposes only.
Semax 30mg is not designated for medical, diagnostic, or therapeutic applications. Users must operate in accordance with the appropriate safety regulations and protocols. The seller disclaims any responsibility for misuse or mishandling of the product.
Bestsellers
